WallStSmart

BeyondSpring Inc (BYSI)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BeyondSpring Inc generates 153% more annual revenue ($1.88M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).

BYSI

Avoid

20

out of 100

Grade: F

Growth: 5.0Profit: 3.0Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: -22.85

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BYSIUndervalued (+86.4%)

Margin of Safety

+86.4%

Fair Value

$10.43

Current Price

$1.71

$8.72 discount

UndervaluedFair: $10.43Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BYSI1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.0110/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

BYSI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$71.55M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BYSI

The strongest argument for BYSI centers on Debt/Equity. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BYSI

The primary concerns for BYSI are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

BYSI is growing revenue faster at 14.3% — sustainability is the question.

BYSI generates stronger free cash flow (-3M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RVMD scores higher overall (24/100 vs 20/100). BYSI offers better value entry with a 86.4% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BeyondSpring Inc

HEALTHCARE · BIOTECHNOLOGY · USA

BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?